Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm


Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.

Aim(s): To investigate the PFS and OS in patients with NEN treated with multiple series of PRRT at the ENETS center of excellence at Aarhus University Hospital.

Materials and methods: Data from 150 patients with NEN in the gastrointestinal (GI) and bronchopulmonary (BP) system, were retrospectively reviewed. Kaplan-Meier estimation was used to determine progression-free survival (PFS) and overall survival (OS) with subgroup analysis by primary tumor, Ki67-index, type of radioisotope and number of PRRT series.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,

Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,

To read the full abstract, please log into your ENETS Member account.